<DOC>
	<DOCNO>NCT02812277</DOCNO>
	<brief_summary>This single centre , observational retrospective clinical study . The study group HR positive postmenopausal breast cancer patient hospitalize January , 2008 October , 2010 , ever accept AI therapy complete follow-up data .</brief_summary>
	<brief_title>Retrospective Analysis Effectiveness Safety Profile Anastrozole Letrozole HR+ Breast Cancer Patients</brief_title>
	<detailed_description>The department surgery Tian Jin Medical University Cancer Hospital , one center excellence treat patient breast cancer China , collect maintain electronic database patient treatment detail follow data . This single centre , observational retrospective clinical study . The study group HR positive postmenopausal breast cancer patient hospitalize January , 2008 October , 2010 , ever accept AI therapy complete follow-up data.All enrol patient receive breast-conserving surgery whole breast surgery , afterwards , receive adjuvant chemotherapy accord pathological type . The patient 's clinical pathological data include age , family history , surgery option , pathologic type , size tumor , lymph node status , histological grade , chemotherapy regime , irradiation regime , expression pattern Her-2 Ki-67 . The research start patient receive first time AI treatment . In subsequent treatment , analyze patient ' bone density change ( T value &gt; -1 indicate normal , -2.5≤T value≤-1 indicates mild osteoporosis , T value &lt; -2.5 indicate severe osteoporosis ) half year 3 year , analyze patient ' liver function kidney function change half year 3 year ( AST , ALT , ALP , TBIL , DBIL , UREA CREA value &gt; 2 time ULN indicate abnormal ) , analyzed patient ' blood-lipoids ( LDL , HDL , TG TC ) half year 3 year , occurrence rate adverse reaction ( skin flush , joint pain , headache , rash , nausea , vomit , diarrhea , et al ) , cause rate treatment termination 2 group , 3 year DFS OS two group , factor associate survival prognosis , identify benefit individual AI therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 ) . Breast cancer confirm histology cytology tumor complete resection 2 ) . ER /or PR positive 3 ) . Postmenopausal woman , define woman fulfil 1 follow criterion ( base NCCN definition menopause [ National Comprehensive Cancer Network 2008 ] ) : 1 . Prior bilateral oophorectomy ; 2 . Age ≥ 60 year ; 3 . Age &lt; 60 year amenorrheic 12 month absence chemotherapy , tamoxifen , toremifene , ovarian suppression plasma FSH estradiol postmenopausal range ; take tamoxifen toremifene , age &lt; 60 year , serial measurement plasma FSH estradiol need ensure postmenopausal range . 4 ) . Patients receive regular anastrozole letrozole adjuvant treatment 6 ) . The value AST , ALT , ALP , TBIL , UREA , CREA less 2 time ULN begin AI therapy . 7 ) . BMD T &gt; 1 baseline . Any follow regarded criterion exclusion study : 1. . Previous use AIs except anastrozole letrozole 2. . Any severe concomitant condition AI treatment : uncontrolled cardiac disease uncontrolled diabetes mellitus et al .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>anastrozole</keyword>
	<keyword>letrozole</keyword>
	<keyword>postmenopausal patient</keyword>
</DOC>